title: Prognostic significance of early molecular response in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
abstract: A 55-year-old man presented with splenomegaly (10 cm below left costal margin) and leucocytosis (145 × 10(9)/L). Differential showed neutrophilia with increased basophils (2%), eosinophils (1.5%), and left shift including myeloblasts (3%). A diagnosis of chronic myeloid leukemia in chronic phase was established after marrow cytogenetics demonstrated the Philadelphia chromosome. Molecular studies showed a BCR-ABL1 qPCR result of 65% on the International Scale. Imatinib therapy at 400 mg daily was initiated due to patient preference, with achievement of complete hematological response after 4 weeks of therapy. BCR-ABL1 at 1 and 3 months after starting therapy was 37% and 13%, respectively (all reported on International Scale). Is this considered an adequate molecular response?
authors.affiliation: Department of Haematology and Molecular Pathology, SA Pathology, and Discipline of Medicine, School of Medicine, University of Adelaide, Adelaide, SA, Australia; and.
authors.forename: David T
authors.initials: DT
authors.lastname: Yeung
authors.affiliation: Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center, New York, NY.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Mauro
mesh_terms: D018572:Disease-Free Survival; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D017410:Practice Guidelines as Topic; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D047428:Protein Kinase Inhibitors